Nothing Special   »   [go: up one dir, main page]

MX357770B - Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. - Google Patents

Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.

Info

Publication number
MX357770B
MX357770B MX2013002722A MX2013002722A MX357770B MX 357770 B MX357770 B MX 357770B MX 2013002722 A MX2013002722 A MX 2013002722A MX 2013002722 A MX2013002722 A MX 2013002722A MX 357770 B MX357770 B MX 357770B
Authority
MX
Mexico
Prior art keywords
sdf
disorder
disease
nucleic acids
cancer treatment
Prior art date
Application number
MX2013002722A
Other languages
English (en)
Other versions
MX2013002722A (es
Inventor
Klussmann Sven
Eulberg Dirk
Maasch Christian
Buchner Klaus
Jarosch Florian
Purschke Werner
Dinse Nicole
Zboralski Dirk
Original Assignee
Noxxon Pharma Ag Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag Star filed Critical Noxxon Pharma Ag Star
Publication of MX2013002722A publication Critical patent/MX2013002722A/es
Publication of MX357770B publication Critical patent/MX357770B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una molécula de ácido nucleico con la capacidad de enlazar a SDF-1, preferentemente con la capacidad de inhibir SDF-1, en donde la molécula de ácido nucleico es para utilizarse en un método para el tratamiento y/o prevención de una enfermedad o trastorno, para utilizarse en un método para tratamiento de un sujeto que padece de una enfermedad o trastorno o que está en riesgo de desarrollar una enfermedad o trastorno como una terapia adjunta, o para utilizarse como un medicamento para el tratamiento y/o prevención de una enfermedad o trastorno, en donde la enfermedad o trastorno es cáncer.
MX2013002722A 2010-09-09 2011-09-09 Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. MX357770B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10009397 2010-09-09
PCT/EP2011/004554 WO2012031773A1 (en) 2010-09-09 2011-09-09 Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Publications (2)

Publication Number Publication Date
MX2013002722A MX2013002722A (es) 2013-06-28
MX357770B true MX357770B (es) 2018-07-24

Family

ID=44653255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002722A MX357770B (es) 2010-09-09 2011-09-09 Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.

Country Status (14)

Country Link
US (3) US20130310442A1 (es)
EP (1) EP2613789B1 (es)
JP (1) JP6243736B2 (es)
KR (1) KR101937939B1 (es)
CN (1) CN103108641B (es)
AU (1) AU2011300818B2 (es)
BR (1) BR112013005664B8 (es)
CA (1) CA2810950C (es)
DK (1) DK2613789T3 (es)
ES (1) ES2678497T3 (es)
MX (1) MX357770B (es)
RU (1) RU2679495C2 (es)
SG (2) SG10201506725QA (es)
WO (1) WO2012031773A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013005664B8 (pt) * 2010-09-09 2023-04-25 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf-1 e uso dos mesmos no tratamento de câncer
WO2017178119A1 (en) * 2016-04-15 2017-10-19 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
ES2525669T3 (es) 1998-03-24 2014-12-29 Chugai Seiyaku Kabushiki Kaisha Inhibidores de la vascularización
EP1068357B2 (en) * 1998-03-30 2014-12-10 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
DE60110593T2 (de) * 2000-06-26 2006-01-19 Wellstat Biologics Corp. Entfernung von zellen mit viren
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
WO2002101350A2 (en) 2001-06-07 2002-12-19 Chemocentryx Cell migration assay
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
WO2003035665A1 (de) 2001-10-26 2003-05-01 Noxxon Pharma Ag Modifizierte l-nukleinsäure
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ATE441706T1 (de) 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
WO2004087068A2 (en) * 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
NZ542687A (en) 2003-04-13 2010-02-26 Enzon Pharmaceuticals Inc Polymeric oligonucleotide prodrugs
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
EP2087910B1 (en) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymeric prodrugs
WO2006052790A2 (en) 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
EP1883651A1 (en) * 2005-05-26 2008-02-06 Rappaport Family Institute For Research in the Medical Sciences Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions
EP1951046B1 (en) * 2005-08-19 2012-07-18 Genzyme Corporation Methods to enhance chemotherapy
KR101466931B1 (ko) * 2006-07-18 2014-12-02 녹손 파르마 아게 Sdf-1 결합형 b형 핵산분자
ES2396220T3 (es) * 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
US8906680B2 (en) * 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
PT2190991T (pt) * 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
BR112013005664B8 (pt) * 2010-09-09 2023-04-25 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf-1 e uso dos mesmos no tratamento de câncer

Also Published As

Publication number Publication date
ES2678497T3 (es) 2018-08-13
EP2613789A1 (en) 2013-07-17
KR101937939B1 (ko) 2019-01-11
DK2613789T3 (en) 2018-07-23
CN103108641A (zh) 2013-05-15
HK1184699A1 (zh) 2014-01-30
BR112013005664B1 (pt) 2021-11-03
RU2013115739A (ru) 2014-10-20
WO2012031773A1 (en) 2012-03-15
CN103108641B (zh) 2016-01-13
AU2011300818B2 (en) 2015-11-12
SG188220A1 (en) 2013-04-30
US20160095875A1 (en) 2016-04-07
EP2613789B1 (en) 2018-04-18
CA2810950C (en) 2023-02-14
AU2011300818A1 (en) 2013-03-07
US9387221B2 (en) 2016-07-12
BR112013005664B8 (pt) 2023-04-25
US10093934B2 (en) 2018-10-09
CA2810950A1 (en) 2012-03-15
BR112013005664A2 (pt) 2020-08-04
JP6243736B2 (ja) 2017-12-06
MX2013002722A (es) 2013-06-28
RU2679495C2 (ru) 2019-02-11
SG10201506725QA (en) 2015-10-29
KR20130114094A (ko) 2013-10-16
JP2013540725A (ja) 2013-11-07
US20130310442A1 (en) 2013-11-21
US20160355821A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2012062925A3 (en) Compounds and methods for treating pain
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
MX362550B (es) Inhibidores ciclicos de glutaminasa.
NZ700759A (en) Combination therapy for treating cancer
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2012038504A3 (en) Breast cancer therapeutics
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
EA201491726A1 (ru) Конъюгаты бороновых кислот олигонуклеотидных аналогов
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
BR112013029182A2 (pt) método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
MX357770B (es) Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer
WO2010108657A3 (en) C5a binding nucleic acids and the use thereof

Legal Events

Date Code Title Description
FG Grant or registration